Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform

被引:5
作者
Valent, Peter [1 ,2 ]
Stauder, Reinhard [3 ]
Theurl, Igor [4 ]
Geissler, Klaus [5 ]
Sliwa, Thamer [6 ]
Sperr, Wolfgang R. [1 ,2 ]
Bettelheim, Peter [7 ]
Sill, Heinz [8 ]
Pfeilstoecker, Michael [2 ,6 ]
机构
[1] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[3] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria
[4] Med Univ Innsbruck, Dept Internal Med Infect Dis Immunol Rheumatol Pn, Innsbruck, Austria
[5] Hosp Hietzing, Med Dept Hematol Oncol & Palliat Med 5, Vienna, Austria
[6] Hanusch Hosp, Med Dept 3, Vienna, Austria
[7] Elisabethinen Hosp, Dept Internal Med, Linz, Austria
[8] Med Univ Graz, Div Hematol, Dept Internal Med, Graz, Austria
关键词
Myelodysplastic syndromes; iron overload; chelation therapy; ferritin; response criteria; TRANSFUSION-DEPENDENT PATIENTS; PROGNOSTIC SCORING SYSTEM; WORLD-HEALTH-ORGANIZATION; STEM-CELL TRANSPLANTATION; PATIENT-RELATED FACTORS; IPSS RISK MDS; CHELATION-THERAPY; ACUTE-LEUKEMIA; CONSENSUS STATEMENT; STIMULATING AGENTS;
D O I
10.1080/17474086.2018.1420473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Despite the availability of effective iron chelators, transfusion-related morbidity is still a challenge in chronically transfused patients with myelodysplastic syndromes (MDS). In these patients, transfusion-induced iron overload may lead to organ dysfunction or even organ failure. In addition, iron overload is associated with reduced overall survival in MDS.Areas covered: During the past 10years, various guidelines for the management of MDS patients with iron overload have been proposed. In the present article, we provide our updated recommendations for the diagnosis, prevention and therapy of iron overload in MDS. In addition, we propose refined treatment response criteria. As in 2006 and 2007, recommendations were discussed and formulated by participants of our Austrian MDS platform in a series of meetings in 2016 and 2017.Expert commentary: Our updated recommendations should support early recognition of iron overload, optimal patient management and the measurement of clinical responses to chelation treatment in daily practice.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 83 条
[1]  
Alessandrino EP, 2002, HAEMATOLOGICA, V87, P1286
[2]   Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial) [J].
Angelucci, Emanuele ;
Santini, Valeria ;
Di Tucci, Anna Angela ;
Quaresmini, Giulia ;
Finelli, Carlo ;
Volpe, Antonio ;
Quarta, Giovanni ;
Rivellini, Flavia ;
Sanpaolo, Grazia ;
Cilloni, Daniela ;
Salvi, Flavia ;
Caocci, Giovanni ;
Molteni, Alfredo ;
Vallisa, Daniele ;
Voso, Maria Teresa ;
Fenu, Susanna ;
Borin, Lorenza ;
Latte, Giancarlo ;
Alimena, Giuliana ;
Storti, Sergio ;
Piciocchi, Alfonso ;
Fazi, Paola ;
Vignetti, Marco ;
Tura, Sante .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (06) :527-536
[3]  
[Anonymous], 2005, HEMATOL ONCOL CLI S1
[4]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[5]   Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT [J].
Armand, P. ;
Sainvil, M-M ;
Kim, H. T. ;
Rhodes, J. ;
Cutler, C. ;
Ho, V. T. ;
Koreth, J. ;
Alyea, E. P. ;
Neufeld, E. J. ;
Kwong, R. Y. ;
Soiffer, R. J. ;
Antin, J. H. .
BONE MARROW TRANSPLANTATION, 2013, 48 (01) :146-147
[6]   Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation [J].
Armand, Philippe ;
Kim, Haesook T. ;
Cutler, Corey S. ;
Ho, Vincent T. ;
Koreth, John ;
Alyea, Edwin P. ;
Soiffer, Robert J. ;
Antin, Joseph H. .
BLOOD, 2007, 109 (10) :4586-4588
[7]   Mutational profiling in patients with MDS: Ready for every-day use in the clinic? [J].
Bacher, Ulrike ;
Kohlmann, Alexander ;
Haferlach, Torsten .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (01) :32-42
[8]   Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes [J].
Bejar, Rafael ;
Levine, Ross ;
Ebert, Benjamin L. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :504-515
[9]   THE CHRONIC MYELOID LEUKEMIAS - GUIDELINES FOR DISTINGUISHING CHRONIC GRANULOCYTIC, ATYPICAL CHRONIC MYELOID, AND CHRONIC MYELOMONOCYTIC LEUKEMIA - PROPOSALS BY THE FRENCH-AMERICAN-BRITISH-COOPERATIVE-LEUKEMIA-GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, H ;
SULTAN, C ;
COX, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) :746-754
[10]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199